Is Concord Drugs Ltd (538965) a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Concord Drugs Ltd is a average quality company .

Is Concord Drugs Ltd (538965) undervalued or overvalued?

The key valuation ratios of Concord Drugs Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Concord Drugs Ltd (538965) share price return in the past 10 years?

Concord Drugs Ltd share price has appreciated 4.3% annually (CAGR) over the past ten years.

Is Concord Drugs Ltd (538965) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Concord Drugs Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Concord Drugs Ltd (538965)?

Company share prices are keep on changing according to the market conditions. The current trading price of Concord Drugs Ltd (538965) on 30-Apr-2026 16:59:59 at 16:59 is 85.13.

What is the P/E ratio of Concord Drugs?

The latest standalone P/E ratio of Concord Drugs as of 30-Apr-2026 is 212.42.

What is the P/B ratio of Concord Drugs Ltd (538965)?

The latest standalone P/B ratio of Concord Drugs Ltd (538965) as of 30-Apr-2026 is 2.43.

What is the 52-week high and low of Concord Drugs Ltd (538965)?

The 52-week high of Concord Drugs Ltd (538965) is Rs. 92.52 and the 52-week low is Rs. 29.00.

Concord Drugs Ltd (538965) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Concord Drugs Ltd (538965)
Brand: Concord Drugs

Concord Drugs Ltd (538965) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Concord Drugs Ltd (538965)

BSE: 538965 NSE:

Key Metrics

Market Cap

₹112 Cr.

P/E Ratio

212.42

Price to Book (P/B)

2.43

Price to Sales (P/S)

2.32

EV/EBITDA

33.63

Return on Capital Employed (ROCE)

4.73%

Current Price

₹85.1

Return on Equity (ROE)

0.87%

Return on Assets (ROA)

0.51%

Operating Profit Margin

10.2%

Net Profit Margin

0.8%

Gross Profit Margin

5.6%

Book Value per Share

₹35

Sales Growth (YoY)

-14.63%

Sales Growth (3 Years)

-14.44%

Operating Profit Growth (1 Year)

2.17%

Operating Profit Growth (3 Years)

-12.38%

Net Profit Growth (1 Year)

-28.57%

52-Week Low / High

₹29 / 93

Net Profit Growth (3 Years)

-42.92%

Dividend Yield

0.00%

Promoter Holding

54.39%

Pledged shares (%)
of Promoter's holding (%)

0.00%

Check Before You Invest

Q.1 Stock return of Concord Drugs Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 4.3% based on the current price.

Q.1 Revenue growth of Concord Drugs Ltd?

Concord Drugs Ltd revenue growth is -14.6% for FY-2025, which is below its 5-year CAGR of -6.38%, indicating slower growth.

Q.1 Which industry/sub-sector does Concord Drugs Ltd belong to?

Concord Drugs Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.1 Promoter shareholding and pledge status of Concord Drugs Ltd?

Promoters hold 54.39% of the Concord Drugs Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Revenue growth of Concord Drugs Ltd vs industry peers?

Concord Drugs Ltd revenue CAGR is -6.38%, compared to the industry median CAGR of 8.30%, indicating slower growth and losing its market share.

DeciZen - make an informed investing decision on Concord Drugs

Based on:

Data

Overall Rating ⓘ
Login to view analysis. M-Cap below 500cr. High Risk from low Liquidity

1. Quality

2. Valuation

3. Price Trend

Concord Drugs stock performance

Key Ratios

Is Concord Drugs Ltd an attractive stock to invest in?

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	15.9%	8.8%	7.5%	6.2%	6.1%	15.7%	9.3%	6%	4.5%	4.7%	-
Value Creation Index ⓘ	0.1	-0.4	-0.5	-0.6	-0.6	0.1	-0.3	-0.6	-0.7	-0.7	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	50.7	57.5	51.8	48.1	51.3	51.4	59	51.3	43.3	36.9	48
Sales YoY Gr.	-	13.4%	-9.9%	-7.2%	6.8%	0%	14.8%	-13%	-15.7%	-14.6%	-
Adj EPS ⓘ	2.5	0.2	0.4	0.5	0.4	0.7	1.8	1	0.4	0.3	0.4
YoY Gr.	-	-91.1%	86.4%	26.8%	-26.9%	94.7%	146%	-47.3%	-56.3%	-28.6%	-
BVPS (₹) ⓘ	20.8	26.2	24.6	29.5	26.9	30.6	32.4	33.4	33.8	34.1	35
Adj Net Profit ⓘ	1.8	0.2	0.3	0.4	0.3	0.7	1.6	0.9	0.4	0.3	1
Cash Flow from Ops. ⓘ	3.6	1.7	6.9	1.2	2.5	1.6	0.8	2.2	2	3.2	-
Debt/CF from Ops. ⓘ	5.5	9.1	2	8.2	3.9	8	21.2	7	7.6	5.4	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-3.5%	-6.4%	-14.4%	-14.6%
Adj EPS ⓘ	-20.9%	-4.6%	-45.2%	-28.6%
BVPSⓘ	5.7%	4.9%	1.7%	0.9%
Share Price	4.3%	23.1%	41.5%	184.2%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	12.6	0.9	1.7	1.9	1.4	2.6	5.8	3	1.3	0.9	1.2
Op. Profit Mgn % ⓘ	16.4	9.6	8.8	7.6	6.5	6.3	9.5	8.5	8.5	10.2	7.8
Net Profit Mgn % ⓘ	3.5	0.3	0.6	0.9	0.6	1.3	2.7	1.7	1	0.8	1.1
Debt to Equity ⓘ	1.3	0.8	0.7	0.4	0.4	0.5	0.6	0.5	0.4	0.5	-
Working Cap Days ⓘ	263	251	474	620	416	293	241	296	348	414	181
Cash Conv. Cycle ⓘ	128	102	129	146	199	217	189	217	242	283	73

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	0.4	0.4
TTM Sales (₹ Cr.)	48.3	51.2
BVPS (₹) ⓘ	35	35
Reserves (₹ Cr.) ⓘ	33	33
P/BV ⓘ	2.43	2.43
PE ⓘ	212.42	198.16

From the Market
52 Week Low / High (₹)	29.00 / 92.52
All Time Low / High (₹)	11.68 / 92.52
Market Cap (₹ Cr.)	112
Equity (₹ Cr.)	13.2
Face Value (₹)	10
Industry PE ⓘ	43.4

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Concord Drugs - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	51	57	52	48	51	51	59	51	43	37
Operating Expenses ⓘ +	42	52	47	44	48	48	53	47	40	33
Manufacturing Costs	16	10	11	10	17	16	16	13	7	7
Material Costs	24	37	34	31	27	27	27	29	27	21
Employee Cost	2	3	2	2	3	3	4	4	4	3
Other Costs ⓘ	1	2	1	1	1	1	7	2	2	2
Operating Profit ⓘ	8	6	5	4	3	3	6	4	4	4
Operating Profit Margin (%)	16.3%	9.6%	8.8%	7.6%	6.5%	6.3%	9.5%	8.5%	8.5%	10.2%
Other Income ⓘ +	0	0	0	0	0	0	0	0	0	0
Exceptional Items ⓘ	0	0	0	0	0	4	0	0	0	0
Interest ⓘ	3	2	2	2	2	1	2	2	2	2
Depreciation ⓘ	3	3	2	2	1	1	2	2	2	1
Profit Before Tax ⓘ	3	1	1	0	0	4	2	1	1	1
Tax ⓘ	1	0	0	0	0	1	1	0	0	0
Profit After Tax	2	0	0	0	0	3	2	1	0	0
PAT Margin (%)	3.5%	0.3%	0.6%	0.9%	0.6%	6.4%	2.7%	1.7%	1.0%	0.8%
Adjusted EPS (₹)	2.4	0.2	0.4	0.5	0.4	3.8	1.8	1.0	0.4	0.3
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	15	19	19	23	23	27	28	31	34	34
Share Capital ⓘ	7	7	8	8	9	9	9	9	10	10
Reserves ⓘ	8	12	11	15	15	18	20	22	24	24
Debt +	20	15	12	10	10	13	16	15	14	15
Long Term Debt	12	6	3	1	1	4	2	1	0	1
Short Term Debt	8	9	9	9	9	9	14	14	14	14
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	10	16	66	43	9	3	7	5	3	3
Others Liabilities ⓘ	8	5	8	7	16	7	5	6	5	6
Total Liabilities ⓘ	52	56	106	83	58	50	56	57	56	59
Fixed Assets
Net Fixed Assets ⓘ +	15	14	14	12	11	13	13	12	11	12
Gross Block	27	29	31	31	31	35	36	37	37	39
Accumulated Depreciation	12	15	17	19	20	21	23	25	26	28
CWIP ⓘ	0	0	0	0	1	0	1	1	2	2
Investments ⓘ	0	0	0	0	0	0	0	1	2	2
Inventories	8	11	19	19	16	12	17	18	18	19
Trade Receivables	25	16	71	48	25	21	23	16	14	13
Cash Equivalents	0	0	0	0	0	0	0	0	0	0
Others Assets ⓘ	4	15	3	3	5	4	2	8	9	11
Total Assets ⓘ	52	56	106	83	58	50	56	57	56	59

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	4	2	7	1	2	2	1	2	2	3
PBT ⓘ	3	1	1	0	0	4	2	1	1	1
Adjustment ⓘ	5	3	4	3	3	3	3	3	3	3
Changes in Working Capital ⓘ	-4	-1	2	-2	-1	-5	-4	-2	-2	-0
Tax Paid ⓘ	-1	-0	-0	-0	-0	-0	-1	-0	-0	-0
Cash Flow From Investing Activity ⓘ +	0	-1	-2	-0	-1	-4	-2	-2	-1	-2
Capex	0	-1	-2	-0	-1	-4	-2	-1	-1	-2
Net Investments	0	0	0	0	0	0	0	-1	0	0
Others ⓘ	0	0	0	0	0	-0	0	0	-0	0
Cash Flow From Financing Activity ⓘ +	-4	-4	-5	-1	-2	2	2	0	-1	-1
Net Proceeds from Shares ⓘ	0	0	3	0	1	0	0	2	1	0
Net Proceeds from Borrowing ⓘ	-0	0	0	-3	0	-0	-1	-1	-1	1
Interest Paid ⓘ	-3	-2	-2	-1	-1	-1	-1	-2	-2	-2
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-1	-2	-6	3	-1	4	4	0	1	-0
Net Cash Flow ⓘ	-0	-3	-0	0	-0	0	0	0	0	-0

Finance Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	12.32	0.94	1.69	1.92	1.41	13.06	5.77	3	1.29	0.87
ROCE (%)	15.9	8.84	7.49	6.17	6.06	15.69	9.3	5.97	4.47	4.73
Asset Turnover Ratio	0.95	1.06	0.64	0.51	0.73	0.95	1.11	0.91	0.77	0.64
PAT to CFO Conversion(x)	2	N/A	N/A	N/A	N/A	0.67	0.5	2	N/A	N/A
Working Capital Days
Receivable Days	190.40	130.60	305.90	454	262.60	164.10	134.90	139.50	127.90	131.70
Inventory Days	49.60	60.90	104.50	141.40	124.70	100.60	90.90	124.50	151.90	185.90
Payable Days	211.50	128.30	443.90	644.10	353.90	81.10	69.70	77.60	56.40	56.20

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Concord Drugs Ltd FAQs

The current trading price of Concord Drugs on 30-Apr-2026 16:59 is ₹85.13.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 29-Apr-2026 the market cap of Concord Drugs stood at ₹112.2 Cr

The latest P/E ratio of Concord Drugs as of 29-Apr-2026 is 212.4.

The latest P/B ratio of Concord Drugs as of 29-Apr-2026 is 2.43.

The 52-week high of Concord Drugs is ₹92.52 and the 52-week low is ₹29.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Concord Drugs is ₹48.26 ( Cr.) .

About Concord Drugs Ltd

No data to display

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Concord Drugs Ltd (538965) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Concord Drugs Share Price